These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 8554529)

  • 1. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide.
    Elass-Rochard E; Roseanu A; Legrand D; Trif M; Salmon V; Motas C; Montreuil J; Spik G
    Biochem J; 1995 Dec; 312 ( Pt 3)(Pt 3):839-45. PubMed ID: 8554529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells.
    Legrand D; van Berkel PH; Salmon V; van Veen HA; Slomianny MC; Nuijens JH; Spik G
    Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):841-6. PubMed ID: 9581564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis.
    van Veen HA; Geerts ME; van Berkel PH; Nuijens JH
    Eur J Biochem; 2004 Feb; 271(4):678-84. PubMed ID: 14764083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein.
    Elass-Rochard E; Legrand D; Salmon V; Roseanu A; Trif M; Tobias PS; Mazurier J; Spik G
    Infect Immun; 1998 Feb; 66(2):486-91. PubMed ID: 9453600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of monoclonal antibodies against human lactoferrin.
    van Berkel PH; van Veen HA; Geerts ME; Nuijens JH
    J Immunol Methods; 2002 Sep; 267(2):139-50. PubMed ID: 12165435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis.
    van Berkel PH; Geerts ME; van Veen HA; Kooiman PM; Pieper FR; de Boer HA; Nuijens JH
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):107-14. PubMed ID: 7492299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice.
    Håversen LA; Engberg I; Baltzer L; Dolphin G; Hanson LA; Mattsby-Baltzer I
    Infect Immun; 2000 Oct; 68(10):5816-23. PubMed ID: 10992490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific binding of lactoferrin to Escherichia coli isolated from human intestinal infections.
    Naidu SS; Erdei J; Czirók E; Kalfas S; Gadó I; Thorén A; Forsgren A; Naidu AS
    APMIS; 1991 Dec; 99(12):1142-50. PubMed ID: 1772651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding of lactoferrin to glycosaminoglycans on enterocyte-like HT29-18-C1 cells is mediated through basic residues located in the N-terminus.
    El Yazidi-Belkoura I; Legrand D; Nuijens J; Slomianny MC; van Berkel P; Spik G
    Biochim Biophys Acta; 2001 Dec; 1568(3):197-204. PubMed ID: 11786226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactoferrin-binding proteins in Shigella flexneri.
    Tigyi Z; Kishore AR; Maeland JA; Forsgren A; Naidu AS
    Infect Immun; 1992 Jul; 60(7):2619-26. PubMed ID: 1319403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.
    van Berkel PH; Geerts ME; van Veen HA; Mericskay M; de Boer HA; Nuijens JH
    Biochem J; 1997 Nov; 328 ( Pt 1)(Pt 1):145-51. PubMed ID: 9359845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex.
    Baveye S; Elass E; Fernig DG; Blanquart C; Mazurier J; Legrand D
    Infect Immun; 2000 Dec; 68(12):6519-25. PubMed ID: 11083760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical characterization of bovine lactoferrin as a glycyrrhizin-binding protein in vitro.
    Tanigawa K; Fujihara M; Furuya T; Shimoyama Y; Morishima N; Ohtsuki K
    Biol Pharm Bull; 2000 Apr; 23(4):438-42. PubMed ID: 10784423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the first N-terminal basic cluster of human lactoferrin (R2R3R4R5) in the interactions with the Jurkat human lymphoblastic T-cells.
    Legrand D; van Berkel PH; Salmon V; van Veen HA; Slomianny MC; Nuijens JH; Spik G
    Adv Exp Med Biol; 1998; 443():49-55. PubMed ID: 9781342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides from the N-terminal end of bovine lactoferrin induce apoptosis in human leukemic (HL-60) cells.
    Roy MK; Kuwabara Y; Hara K; Watanabe Y; Tamai Y
    J Dairy Sci; 2002 Sep; 85(9):2065-74. PubMed ID: 12362437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human intelectin binds bovine lactoferrin and its peptides.
    Shin K; Wakabayashi H; Yamauchi K; Yaeshima T; Iwatsuki K
    Biol Pharm Bull; 2008 Aug; 31(8):1605-8. PubMed ID: 18670097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a bovine lactoferrin binding protein of Streptococcus uberis.
    Moshynskyy I; Jiang M; Fontaine MC; Perez-Casal J; Babiuk LA; Potter AA
    Microb Pathog; 2003 Nov; 35(5):203-15. PubMed ID: 14521879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution.
    Moore SA; Anderson BF; Groom CR; Haridas M; Baker EN
    J Mol Biol; 1997 Nov; 274(2):222-36. PubMed ID: 9398529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical cation-exchange chromatography to assess the identity, purity, and N-terminal integrity of human lactoferrin.
    van Veen HA; Geerts ME; van Berkel PH; Nuijens JH
    Anal Biochem; 2002 Oct; 309(1):60-6. PubMed ID: 12381362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in antimicrobial activity of lactoferricin-derived peptides explained by structure modelling.
    Farnaud S; Patel A; Odell EW; Evans RW
    FEMS Microbiol Lett; 2004 Sep; 238(1):221-6. PubMed ID: 15336425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.